Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
According to the results of a recent study conducted by researchers at the USDA-Agricultural Research Service Western Human Nutrition Research Center, the Northwest Cherry Growers are pleased to announce that consuming about 45 (280 g) sweet Bing cherries significantly decreased circulating concentrations of specific inflammatory biomarkers in the blood. According to Dr. Kent Erickson, Professor at UC Davis School of Medicine and a collaborator in the study, “Many studies by other investigators have demonstrated that some of those inflammation markers are associated with increased risk for some chronic diseases such as cardiovascular disease, diabetes, and cancer.” The findings of the study have been published in the March 2013 issue of The Journal of Nutrition.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61851-northwest-cherries-usda-study-health-benefits
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
Welcome to the ad:tech London multimedia platform. This is a place for brands, agencies, publishers and technology professionals to access video content, news releases, blogs, case studies and reports relating to the UK’s largest digital marketing and media show. We have built this platform to complement the ad:tech exhibition and conference visitor experience so whether you are a brand or agency marketer, media owner advertising professional, technology supplier or member of the press, you will find the site packed with useful content and insight to support your digital marketing and media strategy.
To view Multimedia News Release, go to http://www.multivu.com/players/English/51358-adtech-london-multimedia-platform/
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Centennial College's Police Foundations program is a two-year program that consists of intense training equivalent to that of a paramilitary environment, which helps students to develop discipline and deportment. Courses are based on real-life experiences and case studies that incorporate a fundamental perspective on life. The program successfully prepares graduates for careers in the various police and military forces or in the field of security and related occupations and they have the ability to withstand pressure, communicate effectively, act as problem-solvers and help people in the community.
A level IV trauma center in Washington State has installed copper components throughout its facility as another way of reducing hospital-acquired infections and keeping their patients safe.
Pullman Regional Hospital has become an early adopter of antimicrobial copper after studies found that the age-old metal could continuously kill deadly bacteria.
Each year, 2 million people in the United States are diagnosed with a hospital-acquired infection and nearly 100,000 people die. These infections are caused by common bacteria such as E. coli, MRSA, C. diff, CRE and VRE.
“It is a very serious problem,” said Ed Harrich, the director of surgical services for Pullman Regional Hospital. “I think every hospital across the nation is doing everything they can to try to deal with it the best that they can. But there’s bioburden on everything and people aren’t good at hand washing and there’s cross-contamination everywhere you go.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7378651-copper-development-association-cda-pullman-regional-hospital-keep-patients-safe-antimicrobial-copper/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
